• Vortioxetine significantly reduces depressive symptoms compared to placebo, with a mean difference of -2.31 on the MADRS scale.
• It shows comparable efficacy to SNRIs but with a lower risk of sexual dysfunction and weight gain, improving patient adherence.
• The most common adverse event is nausea, occurring in about 25% of patients, but discontinuation rates due to AEs are similar to placebo.
• Vortioxetine offers a favorable benefit-risk profile, particularly for patients concerned about sexual and metabolic side effects.